Tumor-immunotherapy with the use of tumor-antigen-pulsed antigen-presenting cells.
Our previous study demonstrated that the administration of antigen-presenting cells (APC) pulsed with tumor cell membrane fraction to naive syngeneic mice results in effective induction of tumor-specific protective immunity in vivo. The present study examined whether tumor-antigen-pulsed APC can produce the inhibitory effect on the growth of tumor cells when administered to tumor-bearing hosts. Naive BALB/c mice were inoculated with viable tumor cells. Five days later, these mice started to receive the relevant tumor-antigen-pulsed APC at 3- to 4-day intervals. The administration of tumor-antigen-pulsed APC induced the rejection or growth inhibition of a growing tumor in approximately half of the recipient mice. Moreover, it was demonstrated that tumor-specific immunity was induced in such tumor-regressed mice. These results indicate that tumor-antigen-pulsed APC are effectively applicable to the tumor-specific immunotherapy.
Zou
J P
JP
Biomedical Research Center, Osaka University Medical School, Japan.
Shimizu
J
J
Ikegame
K
K
Takiuchi
H
H
Fujiwara
H
H
Hamaoka
T
T
D000818:Animals; D000938:Antigen-Presenting Cells / Q000637:transplantation*; D000951:Antigens, Neoplasm / Q000276:immunology*; D002462:Cell Membrane / Q000276:immunology; D007111:Immunity, Cellular; D007167:Immunotherapy; D008212:Lymphocyte Depletion; D051379:Mice; D008807:Mice, Inbred BALB C; D012513:Sarcoma, Experimental / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology*; D014407:Tumor Cells, Cultured
D000951:Antigens, Neoplasm